<DOC>
	<DOCNO>NCT01483599</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety CNTO 1959 treatment patient moderate severe plaque psoriasis .</brief_summary>
	<brief_title>A Study Evaluate CNTO 1959 Treatment Patients With Moderate Severe Plaque-type Psoriasis</brief_title>
	<detailed_description>This multicenter , dose-ranging study CNTO 1959 patient moderate severe plaque psoriasis . Patients satisfy inclusion exclusion criterion assign chance one 7 treatment group : placebo group ( placebo treatment identical appearance CNTO 1959 contain active drug ) , 1 5 dose group CNTO 1959 , adalimumab . Patients assign adalimumab dose accord label dosing psoriasis . At Week 16 , patient initially assign placebo begin receive CNTO 1959 . Patients initially assign CNTO 1959 continue receive assign dose level study agent Week 16 Week 40 . Patients receive adalimumab continue label dose regimen . All patient reassess clinical response every 4 week Week 4 Week 40 . Patients continue dose Week 40 , subsequent efficacy safety follow-up visit Week 52 . Patient safety monitor throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis plaquetype psoriasis without psoriatic arthritis least 6 month prior first administration study agent Must candidate phototherapy systemic treatment psoriasis ( either new treatment previous treatment ) Must consider , opinion investigator , suitable candidate adalimumab therapy If woman , must postmenopausal , premenopausal , must either surgically sterile , practice highly effective method birth control , heterosexually active study 5 month receive last dose study drug If man , must agree use doublebarrier method birth control ( must surgically sterilize ) donate sperm study 5 month receive last dose study drug . History current sign symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease Has contraindication antiTNF therapy Has history chronic recurrent infectious disease Has nonplaque form psoriasis druginduced psoriasis Has previously treat adalimumab Has receive therapeutic agent directly target IL12 , IL17 , IL23 , ( include limit ustekinumab , briakinumab [ ABT874 ] , AIN457 , SCH900222 ) within 6 month first administration study agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Moderate Severe Plaque-Type Psoriasis</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque-type psoriasis</keyword>
	<keyword>CNTO 1959</keyword>
	<keyword>adalimumab</keyword>
</DOC>